Premium
The adverse events associated with combination immunotherapy in cancers: Challenges and chances
Author(s) -
Zhuo Minglei,
Chi Yujia,
Wang Ziping
Publication year - 2020
Publication title -
asia‐pacific journal of clinical oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.73
H-Index - 29
eISSN - 1743-7563
pISSN - 1743-7555
DOI - 10.1111/ajco.13365
Subject(s) - adverse effect , immunotherapy , medicine , oncology , cancer
With the development of cancer immunotherapy, the combination strategy is becoming prevalent. Multiple relevant clinical trials are ongoing in this field. However, immune‐related adverse events (irAEs) occurred more frequently, showing a different pattern from single‐agent therapy. It is necessary for clinicians to learn about the characteristics of AEs from combination immunotherapy, and master the skills to deal with them. In this article, we reviewed presently published data about AEs from combination immunotherapy of cancers. We believe a full‐scale view about this new treatment strategy will facilitate oncologists to better understand tumor immune response. With cutting edge knowledge, an experienced team can minimize these AEs and help patients to achieve high‐quality long‐term survival.